Product logins

Find logins to all Clarivate products below.


ENT Devices | Market Insights | Europe (Supplemental) | 2023

Despite the impact of the ongoing COVID-19 pandemic, the market is expected to stabilize, following which overall ENT procedure volumes will grow only slightly in Europe through 2030, hampered by growing developments in alternative treatment such as antibiotics and continued effort of various associations to promote alternatives to surgery. However, ongoing adoption of premium-priced devices, innovative devices such as Eustachian tube balloon dilation devices, and a general trend toward flexible endoscopy will drive the minimal growth of this market through 2030.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for ENT devices in Europe across an 11-year period.

Related Medtech Insights Reports

Report
Interventional Cardiology Devices – Market Insights – Europe
The European interventional cardiology device market is highly competitive and poised for moderate growth over the forecast period, driven by increasing PCI volumes for complex CAD cases and the…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Europe
The European EP mapping and ablation device market will grow moderately through 2035, driven by the rising prevalence of cardiac arrhythmias, improved access to treatment, advancements in ablation…
Report
Aortic Repair Devices – Market Insights – Europe
The European aortic stent graft market is the primary driver of growth in the aortic repair device market and will drive revenue expansion over the forecast period, supported by ongoing innovation…
Report
Cardiac Rhythm Management Devices – Market Insights – Europe
The European CRM device market will continue to grow modestly over the forecast period because of rising ICM procedure volumes, the introduction of dual-chamber leadless pacemakers, and increased…
Report
Gastrointestinal Endoscopy Devices – Market Insights – Europe
The European GI endoscopy device market will be driven primarily by the high incidence of gastric cancer and CRC in the region. Market growth will be supported by nationwide CRC and GI cancer…